• mAbxience and Egis collaborate on the commercialization of two biosimilar candidates
• The agreement covers eight Central and Eastern European countries with the potential for expansion into additional territories
• mAbxience will serve as the marketing authorization holder, while Egis will manage commercialization in the designated regions

MADRID, SPAIN, November 12^th, 2024 —mAbxience, a Fresenius Kabi majority-owned group with partial ownership from Insud Pharma, and Egis Pharmaceutical PLC, today announced a new strategic license agreement for the commercialization of biosimilar candidates across key Central and Eastern European markets, including Hungary, Poland, Czech Republic, Slovakia, Romania, Bulgaria, Latvia, and Lithuania. The partnership also includes the option to expand to additional territories in the future.

Under the terms of the agreement, mAbxience will hold the marketing authorization for the biosimilars in these regions, while Egis will manage the commercialization and marketing activities. This collaboration underscores the commitment of both companies to broaden access to essential, high-quality therapies in markets where affordability and accessibility are critical.

José Ramón Millán, Global Partnering & Portfolio Director at mAbxience, commented on the partnership: “We are delighted to partner with Egis to bring our biosimilar candidate to patients in these important Eastern European markets. This agreement strengthens our presence in the region and reaffirms our dedication to ensuring that life-saving treatments are accessible and affordable. We look forward to working closely with Egis to make a significant impact on patient care.”

Dr. Klara Marton, Business Development Director from Egis added: “This collaboration with mAbxience enables us to deliver high value treatments to patients across Central and Eastern Europe. We are proud to join forces with a trusted partner like mAbxience, whose commitment to high-quality, affordable healthcare solutions aligns with our mission to improve patient access and patient outcomes in our region.”

This agreement marks a significant milestone in mAbxience’s expansion into new markets and further reinforces its commitment to providing accessible, high-quality biosimilar therapies to patients worldwide.